Cutler Group LP Arbutus Biopharma Corp Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$1.91 - $2.85 $481 - $718	-252 Reduced 5.3%	4,500 $10,000
Q3 2022 Oct 25, 2022	SELL	$1.88 - $2.88 $763 - $1,169	-406 Reduced 7.87%	4,752 $9,000
Q2 2022 Aug 04, 2022	SELL	$1.98 - $3.17 $83 - $133	-42 Reduced 0.81%	5,158 $13,000
Q1 2022 Apr 14, 2022	SELL	$2.42 - $3.98 $44,779 - $73,645	-18,504 Reduced 78.06%	5,200 $15,000
Q4 2021 Jan 18, 2022	BUY	$3.11 - $4.61 $54,437 - $80,693	17,504 Added 282.32%	23,704 $92,000
Q3 2021 Oct 26, 2021	BUY	$2.65 - $4.62 $2,650 - $4,620	1,000 Added 19.23%	6,200 $26,000
Q3 2020 Oct 27, 2020	BUY	$1.75 - $6.2 $9,100 - $32,240	5,200 New	5,200 $16,000
Q2 2019 Aug 09, 2019	SELL	$1.46 - $4.44 $5,256 - $15,984	-3,600 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$3.41 - $4.57 $10,230 - $13,710	3,000 Added 500.0%	3,600 $12,000
Q4 2018 Feb 05, 2019	BUY	$3.5 - $9.66 $350 - $966	100 Added 20.0%	600 $2,000
Q1 2018 May 11, 2018	SELL	$4.4 - $6.05 $14,080 - $19,360	-3,200 Reduced 86.49%	500 $2,000
Q4 2017 Jan 17, 2018	BUY	$4.45 - $7.7 $10,235 - $17,710	2,300 Added 164.29%	3,700 $18,000
Q3 2017 Oct 17, 2017	BUY	$3.4 - $7.0 $4,760 - $9,800	1,400	1,400 $8,000

189

112M

866K

608K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $495M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.